Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters
Lo, Janeta; Abbara, Suhnyb; Rocha-Filho, Jose Ab; Shturman, Leonb; Wei, Jeffreya; Grinspoon, Steven Ka
aProgram in Nutritional Metabolism, Massachusetts General Hospital, USA
bDivision of Cardiac Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Received 7 April, 2010
Revised 28 April, 2010
Accepted 11 May, 2010
Correspondence to Janet Lo, MD, Program in Nutritional Metabolism, Massachusetts General Hospital, 55 Fruit Street, LON207, Boston, MA 02114, USA. Tel: +1 617 724 9109; fax: +1 617 724 8998; e-mail: firstname.lastname@example.org
Epicardial fat accumulation may have important clinical consequences, yet little is known regarding this depot in HIV patients. We compared epicardial fat volume in 78 HIV-infected men and 32 HIV-negative controls. Epicardial fat volume was higher in HIV-infected patients than that in controls (P = 0.04). In HIV patients, epicardial fat volume was strongly associated with visceral adipose tissue area (ρ = 0.76, P < 0.0001), fasting glucose (ρ = 0.41, P = 0.001) and insulin (ρ = 0.44, P = 0.0003). Relationships with glucose and insulin remained significant controlling for age, race, BMI, adiponectin, visceral adipose tissue and antiretroviral therapy. Epicardial fat may be an important fat depot in HIV-infected patients.
Epicardial adipose tissue is hormonally active tissue that releases adipokines and fatty acids [1,2] and may be important in HIV patients as it shares an embryonic origin with visceral fat . In non-HIV populations, prior studies have shown associations between pericardial or epicardial fat and visceral adipose tissue (VAT) [4,5], insulin resistance , the metabolic syndrome [4,7] and coronary calcifications [7,8]. Although prior studies have investigated epicardial fat thickness by echocardiography in HIV-infected patients [9,10], no studies have compared epicardial fat volume by computed tomography (CT) in HIV and non-HIV groups. In this study, we investigate epicardial fat volume in HIV and non-HIV patients with similar cardiovascular risk factors and body composition indices to determine whether epicardial fat accumulation occurs and the relationship of epicardial fat to metabolic abnormalities, including glucose parameters, in this population.
In a prospectively recruited cohort of HIV patients and HIV-negative controls , we measured epicardial fat volume by multidetector CT (MDCT) and now present novel data comparing epicardial fat volume between the two groups, assessing the relationship of epicardial fat volume with body composition and metabolic parameters.
Participants were recruited based on absence of known heart disease and cardiac symptoms with a goal to recruiting two groups with similar cardiovascular risk factors. Participants were not recruited based on anthropometric or body composition parameters .
Epicardial fat volume measurements were performed by a single experienced reader using a dedicated semiautomatic program (Siemens Medical Solutions Forchheim, Germany) and similar methodology as previously described . A region of interest was traced on the boundaries of the pericardial layers in every 10 mm with interpolation between the superior and inferior boundary. The top limit of the pericardium fat was the middle of the right pulmonary artery and the lower limit was the apex of the pericardial sac. Fat tissue was defined by voxels with Hounsfield unit (HU) between −30 HU to −190 HU . Body composition and metabolic parameters were determined as previously described . Lipodystrophy was scored as previously reported, rating face, extremities, neck or abdomen as 0–2 for each area .
Comparisons between the groups utilized Student's t-test and Wilcoxon test as appropriate. Univariate and multivariate linear regression were performed using SAS JMP (SAS Institute, Cary, North Carolina, USA).
Seventy-eight HIV-infected men and 32 HIV-seronegative men were studied (Table 1). Epicardial fat volume was higher in HIV patients [112 (82–159) cm3] compared to non-HIV-infected controls [85 (58–131) cm3] (P = 0.04). In contrast, VAT, waist circumference, BMI and total body fat were not different between the groups, though the HIV group tended to have less subcutaneous abdominal fat. A minority of participants in each group met criteria for the metabolic syndrome and the proportions did not differ between the groups (Table 1). Sixteen percent of HIV-infected participants reported having a major feature of lipodystrophy (score of 2 at one or more sites).
Relationship of epicardial fat with body composition and metabolic parameters in HIV patients
Epicardial fat was associated with BMI (ρ = 0.48, P < 0.0001), VAT (ρ = 0.76, P < 0.0001), subcutaneous adipose tissue (SAT) (ρ = 0.39, P = 0.002), total fat mass (ρ = 0.62, P < 0.0001) and lean mass (ρ = 0.37, P < 0.004). In a model including BMI, VAT, SAT, total fat mass and lean mass, VAT was the only body composition measurement that remained significantly associated with epicardial fat (β = 0.30 cm3/cm2, P < 0.0001, model r2 = 0.57). Additional sensitivity analysis adjusting for body composition parameters as well as age, protease inhibitor and nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) use also demonstrated similar results. Among HIV-infected patients without the metabolic syndrome, similar results were seen.
Epicardial fat was positively associated with fasting glucose (ρ = 0.41, P = 0.001), fasting insulin (ρ = 0.44, P = 0.0003) and 2-h insulin (ρ = 0.25, P = 0.04) and negatively associated with adiponectin (ρ = −0.26, P = 0.04), CD4 (ρ = 0.28, P = 0.02) and CD8 cells (ρ = 0.39, P = 0.001), but not with C-reactive protein (CRP) (ρ = 0.09, P = 0.47), monocyte chemoattractant protein-1 (ρ = 0.08, P = 0.55) or IL-6 (ρ = −0.05, P = 0.73).
Coronary atherosclerosis and ventricular function
No correlation was found between epicardial fat and plaque volume (ρ = −0.12, P = 0.35), segments with plaque (ρ = −0.06, P = 0.64) or with calcium score (ρ = −0.02, P = 0.89). All but three HIV patients had normal left ventricular function assessed by cardiac CT. Median epicardial fat volume was 156.7 (107.0–241.1) cm3 in the three patients with decreased ventricular function and 110.6 (81.1–158.7) cm3 in HIV patients with normal cardiac function.
Multivariate modeling in HIV patients
Epicardial fat remained significantly associated with fasting glucose (β = 0.10 cm3/mg/dl, P = 0.02) in a model including age, race, BMI, adiponectin, VAT, current protease inhibitor use and current NRTI use. Similar results were seen in modeling with fasting insulin (β = 0.07 cm3/μU/ml, P = 0.03). Self-reported nadir CD4 count was available for 58 HIV-infected patients. After controlling for nadir CD4 count, epicardial fat volume remained significantly associated with fasting glucose (β = 0.08 cm3/mg/dl, P = 0.005) and insulin (β = 0.09 cm3/μU/ml, P = 0.0002).
Relationship of epicardial fat with metabolic parameters in non-HIV-infected patients
Among HIV-negative controls, epicardial fat was associated with age (ρ = 0.51, P = 0.01), Framingham score (ρ = 0.55, P = 0.005), diastolic blood pressure (ρ = 0.57, P = 0.003), 2-h glucose (ρ = 0.59, P = 0.002), BMI (ρ = 0.81, P < 0.0001), total fat (ρ = 0.88, P < 0.0001), SAT (ρ = 0.78, P < 0.0001) and VAT (ρ = 0.85, P < 0.0001).
The current study demonstrates that epicardial fat volume was significantly higher in HIV patients compared to a well-matched control group that did not differ significantly with respect to other body composition parameters. Among HIV patients, epicardial fat volume correlated most highly with visceral obesity, more so than overall adiposity or other body composition parameters.
In a prior study of HIV patients on highly-active antiretroviral therapy (HAART) with lipodystrophy and the metabolic syndrome, epicardial fat thickness measured by echocardiography correlated with VAT and intima–media thickness . In contrast, patients in our study were not recruited based on the presence of fat redistribution or the metabolic syndrome. Moreover, the majority of patients did not have the metabolic syndrome and the relationships with epicardial fat volume were similar and remained highly significant when analysis was limited to only those without the metabolic syndrome.
In this study, we present novel data among HIV patients demonstrating a moderate but significant relationship between glucose parameters and epicardial fat volume that appears to be independent of other factors known to regulate glucose homeostasis, including VAT. Additional studies are needed to determine whether development of excess epicardial adipose tissue contributes to the insulin resistance in this population and whether reducing epicardial fat should be targeted in this regard.
Our current data demonstrate that CD4+ and CD8+ T-lymphocytes are associated with epicardial fat. T-lymphocytes are increased in the adipose tissue of obese humans, potentially playing a role in obesity-related inflammation [14,15]. Studies are needed to assess whether there is an independent relationship between epicardial fat and immune function in HIV-infected patients.
Our data demonstrate for the first time that epicardial adipose tissue, assessed volumetrically by MDCT, is increased in HIV patients and related to visceral adiposity. Epicardial fat is significantly associated with fasting glucose and insulin in HIV-infected patients, independently of traditional factors affecting glucose homeostasis. Investigation of the mechanisms, clinical significance and potential therapeutic strategies for epicardial fat accumulation in HIV patients is needed.
We wish to thank the participants of this study and the Nursing and Bionutrition Staff of the MGH and MIT GCRC. Funding sources were Bristol Myers Squibb Inc., NIH K23 HL092792 (J.L.), K24 DK064545 (S.K.G.), T32 HL076136 (L.S.) and M01 RR01066-25S1.
Funding sources had no role in the design of the study, data analysis or the writing of the article.
Clinical Trial Registration Number: NCT 00455793.
1. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, ArafatF H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003; 108:2460–2466.
2. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005; 2:536–543.
3. Ho E, Shimada Y. Formation of the epicardium studied with the scanning electron microscope. Dev Biol 1978; 66:579–585.
4. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008; 117:605–613.
5. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003; 11:304–310.
6. Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab 2005; 90:6300–6302.
7. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003; 88:5163–5168.
8. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008; 117:605–613.
9. Iacobellis G, Sharma AM, Pellicelli AM, Grisorio B, Barbarini G, Barbaro G. Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res 2007; 5:275–279.
10. Iacobellis G, Pellicelli AM, Sharma AM, Grisorio B, Barbarini G, Barbaro G. Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol 2007; 99:1470–1472.
11. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243–253.
12. Nichols JH, Samy B, Nasir K, Fox CS, Schulze PC, Bamberg F, Hoffmann U. Volumetric measurement of pericardial adipose tissue from contrast-enhanced coronary computed tomography angiography: a reproducibility study. J Cardiovasc Comput Tomogr 2008; 2:288–295.
13. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, Grinspoon S. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86:504–510.
14. Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007; 115:1029–1038.
15. Duffaut C, Zakaroff-Girard A, Bourlier V, Decaunes P, Maumus M, Chiotasso P, et al. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arterioscler Thromb Vasc Biol 2009; 29:1608–1614.
This article has been cited 3 time(s).
AtherosclerosisEpicardial adipose tissue thickness is a predictor for plaque vulnerability in patients with significant coronary artery diseaseAtherosclerosis
Journal of Infectious DiseasesAdipose Tissue and Immune Function: A Review of Evidence Relevant to HIV InfectionJournal of Infectious Diseases
DrugsHIV-Associated Lipodystrophy: Impact of Antiretroviral TherapyDrugs
© 2010 Lippincott Williams & Wilkins, Inc.